Q Research [Pharma] Thread #1

Post news regarding [Pharma] in here, for example about cures, lawsuits, Pharma/food/etc.-fuckery, studies, etc.

ALWAYS use archiving sites like archive.org or archive.is and post original sauce link as well as the archived link

ALWAYS include the date as well, please use American format (MM/DD/YYYY)

When possible, please create a screenshot of the sauce using for example https://web-capture.net

When you post/see a relevant post on Q Research General or any other bread, please post it on here as well

We are researchers who deal in open-source information, reasoned argument, and dank memes. We do battle in the sphere of ideas and ideas only. We neither need nor condone the use of force in our work here.

Welcome to Q Research (README FIRST, THEN PROCEED TO LURK) https://8ch.net/qresearch/welcome.html

CURE NEWS: 08/24/2018

For first time in 40 years, cure for acute leukemia within reach

https://www.eurekalert.org/pub_releases/2018-08/thuo-fft082418.php

http://archive.is/hnU01

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.

As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)'s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.

CURE NEWS: 08/24/2018

New Therapy Could Reverse Type 1 Diabetes In Humans and Dogs

https://www.forbes.com/sites/robinseatonjefferson/2018/08/24/new-therapy-could-reverse-type-1-diabetes-in-humans-and-dogs/

https://web.archive.org/web/20180825113140/www.forbes.com/sites/robinseatonjefferson/2018/08/24/new-therapy-could-reverse-type-1-diabetes-in-humans-and-dogs/

Researchers at Purdue University and Indiana University School of Medicine (IU) are working with man’s best friend to cure one of his most insidious diseases.

The scientists say a new therapy shows promise for long-term reversal of Type 1 diabetes in both humans and dogs.

Purdue reported this week that scientists achieved normal glucose levels in diabetes-induced mice by injecting them with a collagen solution mixed with pancreatic cells. It is the first minimally invasive therapy to successfully reverse Type 1 diabetes within 24 hours and maintain insulin independence for at least 90 days, scientists report.

Researchers effectively ushered in healthy pancreatic cells like a Trojan horse, with the Trojan horse being a protein the body already makes for building muscles, bones, skin and blood vessels—collagen.

CURE NEWS: 09/11/2018

Could this vaccine be the cure to skin cancer?

https://nypost.com/2018/09/11/could-this-vaccine-be-the-cure-to-skin-cancer/

https://web.archive.org/web/20180912052945/https://nypost.com/2018/09/11/could-this-vaccine-be-the-cure-to-skin-cancer/

A new cancer vaccine has shown a 100 percent success rate when treating aggressive melanoma in mice.

Researchers at Scripps Research Institute in La Jolla, Calif., and the University of Texas in Dallas, gave mice suffering from melanoma a cancer immunotherapy drug called anti-PD-L1, which prevents tumor cells from attacking their immune systems. The study found that rodents who were also given Diprovocim, a chemical compound that’s meant to galvanize the immune system, had a 100 percent survival rate.

And attempts to re-introduce cancer tumors in these vaccinated mice failed.

While more research needs to be done to determine the vaccine’s effectiveness in humans, researchers are hopeful about their findings.

CURE NEWS: 09/13/2018

Schizophrenia breakthrough: Scientists identify new suspect at 'scene of crime'

https://www.smh.com.au/healthcare/schizophrenia-breakthrough-scientists-suspect-immune-cells-20180412-p4z986.html

https://web.archive.org/web/20180913130153/https://www.smh.com.au/healthcare/schizophrenia-breakthrough-scientists-suspect-immune-cells-20180412-p4z986.html

As a type of immune cell, it has always been considered one of the good guys. But in a stunning breakthrough in schizophrenia research, scientists say the "macrophage" immune cell can go rogue, causing havoc in the brain.

"Macrophage" means "big eaters" in Greek and is a fitting name for the cell because - when behaving - it digests cellular debris and foreign substances.

Australian researchers have, for the first time, identified the presence of macrophage cells in the brain tissue of a subgroup of people with schizophrenia.

"It's like a murder mystery, one that’s remained unsolved for a hundred years," Professor Cyndi Shannon Weickert from Neuroscience Research Australia (NeuRA) said.

CURE NEWS: 09/24/2018

New Electrical Stimulation Therapy Allows Paralyzed Patients to Walk Again

https://sputniknews.com/science/201809241068298880-Electrical-Therapy-Paralyzed-Walk-Again/

http://archive.is/Suwx0

Two recently published studies demonstrating the ability of epidural electrical stimulation (EES) to restore motor ability in some patients with complete spinal cord injuries provide a powerful proof of concept for healing partially paralyzed people.

Simultaneous studies published in the New England Journal of Medicine and in Nature Medicine on September 24 report that following months of EES, patients who had no "voluntary movement or sphincter function below the level of injury," but retained some sensation, were able to recover some of their mobility and walk upright using a walker.

The second study, done by the Mayo Clinic, reported on only a single patient, but that person, using a similar method for 43 weeks of "dynamic task-specific training in the presence of EES, termed multi-modal rehabilitation (MMR)," was able to regain "bilateral stepping on a treadmill, independent from trainer assistance or BWS [body weight support system]," the study reported. Further, the therapy "enabled independent stepping over ground while using a front-wheeled walker with trainer assistance at the hips to maintain balance" and "engaged sensorimotor networks to achieve dynamic performance of standing and stepping."

CURE NEWS: 09/28/2018

FDA approves first treatment for advanced form of the second most common skin cancer

New drug targets PD-1 pathway

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-advanced-form-second-most-common-skin-cancer-0

http://archive.is/WwySI

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.

Libtayo works by targeting the cellular pathway known as PD-1 (protein found on the body’s immune cells and some cancer cells). By blocking this pathway, the drug may help the body’s immune system fight the cancer cells.

"We’re continuing to see a shift in oncology toward identifying and developing drugs aimed at a specific molecular target. With the Libtayo approval, the FDA has approved six immune checkpoint inhibitors targeting the the PD-1 / PD-L1 pathway for treating a variety of tumors, from bladder to head and neck cancer, and now advanced CSCC,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “This type of cancer can be difficult to treat effectively when it is advanced and it is important that we continue to bring new treatment options to patients."

CURE NEWS: 10/20/2018

Immunotherapy drug showing promise for aggressive type of breast cancer

https://www.cbsnews.com/news/tecentriq-immunotherpy-triple-negative-breast-cancer-shows-promise/

Scientists say a new treatment is showing promise in the fight against aggressive breast cancer. Three years ago, at age 39, Maribel Ramos was diagnosed with advanced breast cancer. The type was triple negative.

"I was angry and sad," Ramos said. "Because I know that the triple negative is a type of cancer that is really hard to treat."

Ten to 20 percent of breast cancers are called triple negative because they don't have receptors - such as ones for estrogen - that can be targeted by certain medications. Treatment options are limited, and these cancers tend to be more aggressive, with worse outcomes.

In 2016, Ramos entered a trial to test the immunotherapy drug Tecentriq on patients with advanced triple negative breast cancer.

CURE NEWS: 10/28/2018

Historic breakthrough: WVU Rockefeller Neuroscience team first to use ultrasound to treat Alzheimer's

https://www.wvnews.com/news/wvnews/historic-breakthrough-wvu-rockefeller-neuroscience-team-first-to-use-ultrasound/article_cfe6fefc-eee9-5add-b853-23642a0a91a7.html

https://web.archive.org/web/20181215220605/https://www.wvnews.com/news/wvnews/historic-breakthrough-wvu-rockefeller-neuroscience-team-first-to-use-ultrasound/article_cfe6fefc-eee9-5add-b853-23642a0a91a7.html

World-leading brain experts at West Virginia University’s Rockefeller Neuroscience Institute are celebrating the historic breakthrough Alzheimer patients around the globe have been awaiting.

"For Alzheimer’s, there’s not that many treatments available, despite hundreds of clinical trials over the past two decades and billions of dollars spent," said Dr. Ali R. Rezai, a neurosurgeon at WVU who led the team of investigators that successfully performed a phase II trial using focused ultrasound to treat a patient with early stage Alzheimer’s.

The WVU team tested the innovative treatment in collaboration with INSIGHTEC, an Israeli medical technology company. Earlier this year, INSIGHTEC was approved by the U.S. Food and Drug Administration to begin a phase II clinical trial of the procedure, and selected the WVU Rockefeller Neuroscience Institute as the first site in the United States for that trial.

Last summer, researchers at Sunnybrook Health Sciences Centre in Toronto reported the results of a phase I safety trial showing they could reversibly open the blood-brain barrier in Alzheimer’s patients.

>>6891745

http://archive.is/R3jF1

CURE NEWS: 11/01/2018

Is an HIV cure on the immediate horizon? A major medical breakthrough delivers hope

https://www.news.com.au/technology/science/human-body/is-an-hiv-cure-on-the-immediate-horizon-a-major-medical-breakthrough-delivers-hope/news-story/73337f26a96c8a794ed7bf29e8f21195

http://archive.is/1ny8U

RESEARCHERS believe they are on the cusp of developing a cure for HIV, after a groundbreaking initial human trial of a drug eliminated the virus.

A TEAM of medical researchers believes they are on the cusp of developing a cure for HIV, after an initial human clinical trial delivered astounding results.

In the first phase of testing, the drug Gammora eliminated up to 99 per cent of the virus within the first four weeks of treatment, it was announced today.

Zion Medical, an Israeli biotech company, has worked in conjunction with the Hebrew University of Jerusalem, on the trials.

The groundbreaking results showed the drug significantly reduced the viral load in human subjects by killing HIV-infected cells without harming healthy ones.

While it’s the first stage of exploration and a small-scale start, it has offered significant hope of a potential cure for the virus, which first emerged 35 years ago.

"These first clinical results were beyond our expectations and promise hope in finding a cure for the disease," Dr Esmira Naftali, head of development at Zion Medical, said.

CURE NEWS: 06/02/2019

Mexican scientist cures the Human Papilloma Virus (HPV)

https://www.eluniversal.com.mx/english/mexican-scientist-cures-human-papilloma-virus

http://archive.is/gBfuy

Eva Ramón Gallegos, a researcher from Mexico National Polytechnic Institute (IPN) was able to completely eradicate the Human Papilloma Virus (HPV) in 29 patients.

This scientific achievement was accomplished through photodynamic therapy, a non-invasive technique that seems to be an efficient method to prevent malignant neoplasm, which is the second cause of death among Mexican women.

The scientists from the National Biological Sciences School explained that she has studied the effects of photodynamic therapy for 20 years and said she was treated 420 patients in Oaxaca and Veracruz with this method, as well as 29 women in Mexico City.

CURE NEWS: 04/08/2019

Cancer 'vaccine' shows promise in human trial of lymphoma patients

https://www.cnbc.com/2019/04/08/cancer-vaccine-shows-promise-in-human-trial-of-lymphoma-patients.html

http://archive.is/mCqkq

An experimental cancer "vaccine" showed promising results in a small clinical trial of patients with lymphoma, according to a study published Monday in the journal Nature Medicine.

Researchers at New York's Mount Sinai Hospital tested the treatment in 11 patients with lymphoma. Their results were successful enough to warrant another clinical trial in March on lymphoma patients as well as breast and head-and-neck cancer.

Researchers said some patients in the initial human trial went into full remission for months or even years.

The treatment "has broad implications for multiple types of cancer," said lead author, Dr. Joshua Brody, director of the lymphoma immunotherapy program. "This method could also increase the success of other immunotherapies such as checkpoint blockade."

CURE NEWS: 04/10/2019

Fecal transplants yield MASSIVE breakthrough for child autism, 50% reduction in severity

https://www.rt.com/news/456148-fecal-transplants-autism-breakthrough/

http://archive.is/vvmB7

Scientists are celebrating a "world-first discovery" which shows the "highest improvement" in child autism patients, using fecal transplants to massively curtail symptoms and greatly reduce suffering.

The results of the initial study involving 18 children show great promise: 83 percent of the children had "severe" autism symptoms, but just two years later, only 17 percent had "moderate" symptoms, while 44 percent fell below the threshold for "mild" autism.

The team recorded a roughly 45-percent drop in language, social, and behavioural issues in the children over the course of the study.

FUCKERY NEWS: 01/10/2019

Oral-B Glide floss tied to potentially toxic PFAS chemicals, study suggests

https://www.usatoday.com/story/news/nation/2019/01/09/oral-b-glide-floss-toxic-pfas-chemicals-study/2530661002/

http://archive.is/XhczM

Using Oral-B Glide dental floss might be associated with higher levels of toxic PFAS chemicals in your body, according to a new peer-reviewed study of consumer behaviors potentially linked to the substances.

PFAS, or per- and polyfluoroalkyl substances, are potentially harmful chemicals often used for their water and grease resistance.

The study, which aimed to explain how these chemicals enter the human body, was published Tuesday in the Journal of Exposure Science & Environmental Epidemiology and comes from the Silent Spring Institute in Newton, Massachusetts, and Public Health Institute in Berkeley, California.

Researchers found higher levels of PFHxS (perfluorohexanesulfonic acid), a PFAS, in women who flossed with Oral-B Glide compared to those who didn't.

"This is the first study to show that using dental floss containing PFAS is associated with a higher body burden of these toxic chemicals," lead author Katie Boronow, a scientist at Silent Spring, said in a statement.

FUCKERY NEWS: 05/07/2019

Sunscreen chemicals seep into your bloodstream after one day of use: study

https://nypost.com/2019/05/07/sunscreen-chemicals-seep-into-your-bloodstream-after-one-day-of-use-study/

http://archive.is/MC4IU

The chemicals in popular sunscreens don’t just sit on the surface of the skin — many of them are absorbed into the bloodstream at levels that far surpass government-recommended thresholds for the compounds, according to a new study.

The results of the study, published Monday in the peer-reviewed journal JAMA, don’t mean that the active ingredients contained in sunscreen are unsafe, according to an editorial accompanying the study, written by Food and Drug Administration chairman Robert Califf and JAMA dermatology editor in chief Kanade Shinkai.

But the findings should give the industry pause, the researchers said.

"The study findings raise many important questions about sunscreen and the process by which the sunscreen industry, clinicians, specialty organizations, and regulatory agencies evaluate the benefits and risks of this topical OTC medication," the authors wrote.

CURE NEWS: 12/18/2018

Biologists identify promising drug for ALS (Lou Gehrig's disease) treatment

https://www.sciencedaily.com/releases/2018/12/181218123120.htm

http://archive.is/5Cpyx

A new drug could significantly slow the progression of ALS, also known as Lou Gehrig's disease, according to new research by University of Alberta biologists. Current treatments slow progression of the degenerative disease by only a few months, and these findings could revolutionize the treatment of patients suffering from ALS, extending and improving quality of life.

The drug, called telbivudine, targets a protein that misfolds and does not function correctly in patients with ALS. "SOD1 is a protein that is known to misfold and misbehave in most cases of patients with ALS," explained Ted Allison, associate professor in the Department of Biological Sciences and co-author on the study. "We showed that telbivudine can greatly reduce the toxic properties of SOD1, including improving the health of the subject's motor neurons and improving movement."

The research team used computer simulations to identify drugs with the potential for targeting the SOD1 protein. From this shortlist, the scientists identified and tested the most likely candidates – including telbivudine – using animal models.

"ALS is not well-understood," said lead author Michele DuVal, who recently completed the PhD portion of the Faculty of Medicine & Dentistry'sMD/PhD program under the supervision of Allison. "We don't yet know exactly what goes wrong first in the motor neurons or how the misbehaving SOD1 causes toxicity. Because there is still much to learn about the disease, the ALS research community focuses on both understanding ALS and on developing promising therapies."

The discovery of telbivudine as a potential treatment is particularly exciting because the drug is already in use for treating patients with hepatitis. "It is already proven safe to use in patients, and it has very good potential for repurposing to use in a new clinical setting against ALS," said Allison.

FUCKERY NEWS: 06/05/2019

Pfizer didn't reveal drug's Alzheimer's preventing abilities

https://thehill.com/homenews/news/447114-drug-company-didnt-reveal-alzheimers-preventing-abilities-report

http://archive.is/fm4oM

A U.S. drug company did not openly share or perform further studies on a successful rheumatoid arthritis medicine that internal researchers suggested was reducing the risk of Alzheimer's disease by 64 percent, according to Washington Post article published Tuesday.

Researchers at Pfizer reportedly urged the firm to conduct a clinical trial after finding the potential hidden benefit of the anti-inflammatory drug Enbrel while analyzing insurance claims.

It was estimated to cost $80 million to conduct the trial, and Pfizer decided to pass.

Pfizer told the Post it did not pursue the clinical trial because its success rate would likely be low.

Enbrel had reached the end of its patent life and its profits were dwindling, meaning it may have made little business sense to invest in the trial, according to the Post.

Outside researchers said it would've helped the medical community for Pfizer to publish its findings, since doing so could have led to further discoveries about the complicated disease.

"It would benefit the scientific community to have that data out there,’’ said Keenan Walker, an assistant professor of medicine at Johns Hopkins who is studying how inflammation contributes to Alzheimer’s. "Whether it was positive data or negative data, it gives us more information to make better informed decisions.’’

At least one medical ethicist agreed.

"Having acquired the knowledge, refusing to disclose it to those who might act upon it hides a potential benefit, and thereby wrongs and probably harms those at risk of developing Alzheimer’s by impeding research,’’ Bobbie Farsides, professor of clinical and biomedical ethics at Brighton and Sussex Medical School in the United Kingdom, told the Post.

FUCKERY NEWS: 11/29/2018

Vaccine Boom, Population Bust: Study Queries the Link Between HPV Vaccine and Soaring Infertility

https://www.theepochtimes.com/vaccine-boom-population-bust-study-queries-the-link-between-hpv-vaccine-and-soaring-infertility_2727094.html

http://archive.is/3qKAY

A plague is spreading silently across the globe. The young generation in America, the United Kingdom, France, Italy, Japan, Australia—in virtually every western country—is afflicted by rapidly increasing rates of infertility.

…

So, earlier this month, when an unprecedented study was released that looked at a database of more than eight million American women and singled out a whopping 25 percent increase in childlessness associated with one ubiquitous drug that young women have been taking for only a decade—in tandem with a marked decline in fecundity—you would have thought there would be significant interest from public health, the medical profession and the media, wouldn’t you?

…

Instead, all three of these behemoths remain stone silent. The reason? Because the study, published in the current Journal of Toxicology and Environmental Health, examines the childbearing capacity of women who received the human papilloma virus (HPV) vaccine—compared to those who didn’t—and the results are chilling. No one in public health, medicine or mainstream media, which are tangled up in the money-making machine of this vaccine, dare to publicly question the “safe and effective” mantra they’ve promulgated about Merck and GSK pharmaceuticals’ “blockbuster” commodity worth billions.

The study is by Gayle DeLong, associate professor of economics and finance, at Baruch College at City University of New York. She observed that the declining birth rate had plunged in America in recent years—from 118 per 1,000 in 2007, to 105 in 2015 for the cohort aged 25 to 29.

The HPV vaccine was approved by the Food and Drug Administration for use in the US in 2006 to prevent cervical cancer—an illness women face a 0.6 percent lifetime risk of being diagnosed with. Although it is diagnosed most frequently at age 47 in the United States, it was rolled out en masse, initially targeting girls aged 11 to 26 (and has since been marketed to boys as young as nine to prevent rare anal and penile cancers—a disease that afflicts 0.2 percent of men in their lifetime.).

FUCKERY NEWS: 03/24/2019

Supermarket ham and bacon may contain 'pointless' chemicals that are linked to cancer, leaked report reveals

https://www.dailymail.co.uk/news/article-6845851/Supermarket-ham-bacon-contain-pointless-chemicals-linked-cancer.html

https://web.archive.org/web/20190325214648/https://www.dailymail.co.uk/news/article-6845851/Supermarket-ham-bacon-contain-pointless-chemicals-linked-cancer.html

• Some meats contain nitrites that are used to preserve the foods and kill bacteria

• These are also used to maintain the meats pink colour because it looks better

• But a leaked report for the British Meat Processors Association suggests they have no effect on botulinum bacteria

• Nitrites have been linked to some cancers but may be a 'pointless' preservative

Chemicals linked to cancer in processed ham and bacon do not need to be used, a leaked report has revealed.

Many of the meats on supermarket shelves contain nitrites – which are both a powerful preservative and are supposed to kill botulinum bacteria, which can cause food poisoning.

However, research for the British Meat Processors Association by the scientific consultancy Campden has revealed that nitrites do not attack the bug.

NEWS: 06/10/2019

Study: Unhealthy Gut Promotes Spread of Breast Cancer

https://news.virginia.edu/content/study-unhealthy-gut-promotes-spread-breast-cancer

http://archive.is/fGOty

An unhealthy, inflamed gut causes breast cancer to become much more invasive and spread more quickly to other parts of the body, new research from the University of Virginia Cancer Center suggests.

Melanie Rutkowski, a research faculty member in UVA’s Department of Microbiology, Immunology and Cancer Biology, found that disrupting the microbiome of mice caused hormone receptor-positive breast cancer to become more aggressive. Altering the microbiome, the collection of microorganisms that live in the gut and elsewhere, had dramatic effects in the body, priming the cancer to spread.

"When we disrupted the microbiome’s equilibrium in mice by chronically treating them with antibiotics, it resulted in inflammation systemically and within the mammary tissue," she said. "In this inflamed environment, tumor cells were much more able to disseminate from the tissue into the blood and to the lungs, which is a major site for hormone receptor-positive breast cancer to metastasize."

FUCKERY NEWS: 12/14/2018

Johnson & Johnson knew for decades that asbestos lurked in its Baby Powder

https://www.reuters.com/investigates/special-report/johnsonandjohnson-cancer/

http://archive.is/KgTfW

Facing thousands of lawsuits alleging that its talc caused cancer, J&J insists on the safety and purity of its iconic product. But internal documents examined by Reuters show that the company's powder was sometimes tainted with carcinogenic asbestos and that J&J kept that information from regulators and the public.

…

J&J didn’t tell the FDA that at least three tests by three different labs from 1972 to 1975 had found asbestos in its talc – in one case at levels reported as “rather high.”

…

NEWS: 05/29/2019

Biological, Behavioral and Physiological Consequences of Drug-Induced Pregnancy Termination at First-Trimester Human Equivalent in an Animal Model

https://www.frontiersin.org/articles/10.3389/fnins.2019.00544/full

http://archive.is/WGCyW

Conclusion

To our knowledge, our study is the first report addressing the potential biological, behavioral and biochemical effects associated with pregnancy termination in an animal model. Additionally, the findings of this study also appear to provide additional support to the current literature pertaining to the benefits of carrying a pregnancy to full-term. Moreover, we believe that our findings support the use of this model as an objective method for the investigation of potential physical (biological and physiological) and behavioral effects of induced pregnancy termination. Our findings strongly suggest that pregnancy termination at mid-term (first-trimester human equivalent) induces significant negative biological and behavioral changes in the rat. Additionally, such a procedure appears to be associated with a potential absence of beneficial effects of carrying a pregnancy to full-term. Moreover, our findings also appear to indicate a significant difference between induced pregnancy termination (medical abortion) and natural miscarriage. Our study, therefore, indicates the importance and necessity for further objective research into the abortion procedure, including at the physiological and neurophysiological levels. Such work may further our understanding and potentially shed some clarity into the potential biobehavioral impact of such a procedure at the level of the human person.

FUCKERY NEWS: 03/11/1999

Poison from the prisons - Tainted blood

https://www.economist.com/united-states/1999/03/11/poison-from-the-prisons

http://archive.is/4mwad

AT THE end of February, a group of Canadian haemophiliacs infected with HIV and hepatitis C descended on Washington. They want an inquiry into why the United States, particularly the federal Food and Drug Administration, allowed the export of tainted prison plasma from Arkansas and Louisiana to Canada in the 1980s. At the time, Bill Clinton was governor of Arkansas, and the FDA had already ruled that prison plasma was too unsafe to be used for the manufacture of blood products inside the United States.

…

Yet not only did the prisons run such a programme from 1969 on, they were often in trouble for it. In Cummins, even when the existence of AIDS and hepatitis C was recognised and tests for these diseases became available, they were not aways used; the FDA discovered that one hepatitis-testing laboratory was out of action for two months. Needles were often dirty, so that many inmates now claim to have been infected as they gave blood. (People caught in homosexual acts were, however, removed from the list of suitable donors.)

…

Francis Henderson, the creator of HMA and chairman of its board, maintains that AIDS cases simply did not exist in the South during the 1980s, and that prison plasma was no riskier than other kinds. However, Art Lockhart, then director of the Arkansas Department of Correction, contributed in 1984 to an information bulletin about prison plasma centres published by the American Correctional Association, in which prison populations were said to be at high risk, and concerns were raised about “quality control” in taking blood from them. Despite this, the Arkansas Department of Correction went on running its plasma programme for another decade.

…

FUCKERY NEWS: 2014

Blood money: Bayer's inventory of HIV-contaminated blood products and third world hemophiliacs.

https://www.ncbi.nlm.nih.gov/pubmed/24785997

https://web.archive.org/web/20150423041754/https://www.ncbi.nlm.nih.gov/pubmed/24785997

Abstract

This article presents an overlooked case of research misconduct and violations of basic principles of medical and business ethics. When Bayer's Cutter Laboratories realized that their blood products, Factor VIII and IX or antihemophiliac factor (AHF), were contaminated with human immunodeficiency virus (HIV), the financial investment in the product was considered too high to destroy the inventory. Cutter misrepresented the results of its own research and sold the contaminated AHF to overseas markets in Asia and Latin America without the precaution of heat treating the product recommended for eliminating the risk. As a consequence, hemophiliacs who infused the HIV-contaminated Factor VIII and IX tested positive for HIV and developed AIDS.

FUCKERY NEWS: 05/23/2003

Bayer division 'knowingly sold' HIV-infected protein

https://www.theguardian.com/world/2003/may/23/aids.suzannegoldenberg

http://archive.is/vxbUN

A division of the German pharmaceutical company Bayer knowingly sold blood-clotting agents infected with HIV to Asia and Latin America months after withdrawing them from Europe and the US, an American newspaper claimed yesterday.

Cutter Biological continued to dump stocks of the factor VIII blood-clotting agent for haemophiliacs on poor countries for nearly a year after introducing a safer alternative, the report in the New York Times said.

It happened in the early 80s, after the Centres for Disease Control in Atlanta, Georgia, reported in July 1982 that haemophiliacs were becoming ill from blood products.

Up to that time factor VIII, produced from the plasma of about 10,000 donors, was not screened for HIV, and it became a leading killer of haemophiliacs in the early years of Aids.